Evaluations
0
Does NICE consider real-world data (RWD) for HTA evaluations? – Healthcare Economist
0

The answer is "yes", but the question is in what way? an article from Che et al. (2024) examines the use of real-world data (RWD) in ETS evaluations from ...

0
Methods for Including Adverse Events in Economic Evaluations – Healthcare Economist
0

That's the title of a great review. Article by Salah Ghabri, Dalia Dawoud and Michael Drummond. This article notes that guidance on incorporating adverse ...

0
Challenges in Conducting Economic Evaluations for Orphan Drugs in Rare Diseases – Healthcare Economist
0

Why is it so difficult to estimate the value of orphan drugs indicated for the treatment of rare diseases? There are a ...

0
Good practices for incorporating family and caregiver spillovers into health economic evaluations – Healthcare Economist
0

Diseases not only affect patients, but often also affect caregivers and family members. However, most economic analyzes ...

0
Trial-Based Economic Evaluations in R – Healthcare Economist
0

A recent article by Ben et al. (2023) provides an R tutorial for implementing economic evaluations (often ...

Tools4BLS
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart